A new AI model, Fragmentia-AI-COAD, reported high-sensitivity detection of colorectal cancer and advanced adenomas from blood-based cell-free DNA fragmentomic signatures. The approach uses a transformer architecture aimed at translating fragmentation patterns into clinically actionable classification. For screening and early diagnosis, the study’s emphasis on performance in detecting advanced adenomas is notable, since these lesions represent a key intervention window. Blood-based strategies are also attractive where colonoscopy access and compliance remain challenging. Industry attention will turn to external validation, prospective performance, and how the model behaves across comorbidities, age groups, and pre-analytical variability in cfDNA handling.